EGFR and neoplasm: In a mouse tumor model, as the tumors became resistant to erlotinib, αvβ3 integrin-negative HCC827 human EGFR-mutant lung tumors not only gained αvβ3 integrin but also became enriched for tumor-associated macrophages (TAMs) [129].